Therapeutic Effects of Pyroglutamate Helix B Surface Peptide (pHBSP) in Disease
Pp. 125-143 (19)
Kiran K. Nandra, Nimesh S.A. Patel and Christoph Thiemermann
Pyroglutamate helix B surface peptide (pHBSP) is an 11 amino acid peptide
based on the tertiary structure of erythropoietin (EPO). EPO is released from the kidney
and its primary function is to control the production of erythrocytes in response to
hypoxia. More recently, EPO has been found to possess many pleiotropic actions, in
particular its ability to protect tissues against injurious stimuli. However, its use in
patients is associated with an increased risk of thrombotic events due to the stimulation
of erythropoiesis, this has led to the development of multiple EPO analogues including
pHBSP. pHBSP has demonstrated its tissue-protective capability in many pre-clinical
studies, with effects comparable to those of EPO. pHBSP is proposed to act via a
receptor structurally distinct to the classical EPO receptor homodimer; the β-common
receptor (βcR), therefore it does not induce erythropoiesis. pHBSP is a novel and
attractive therapeutic intervention for the treatment of many disease states including
acute kidney injury, stroke and myocardial infarction, however there are currently no
clinical studies using this peptide.
Pyroglutamate helix B surface peptide, erythropoietin, tissue-protection,
apoptosis, inflammation, β-common receptor.
Centre for Translational Medicine and Therapeutics, The William Harvey Research Institute, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK.